Regulatory affairs is one of the most painful jobs in biotech. You spend months, sometimes years, sifting through FDA guidance documents, EMA opinions, prior approval precedents, and clinical review letters, trying to reverse-engineer what a regulator will think before they think it. Get it wrong and your drug program gets delayed or killed. Get it right and you just saved your company a billion dollars and a few years of human life.
That's the market Rhizome AI is walking into with a deceptively simple pitch: always know what the FDA thinks. Under the hood it's a RAG system built on a 2.5TB proprietary corpus of regulatory intelligence spanning 44 million documents across 43 datasets and 10 countries. But calling it "just RAG" is like calling a Bloomberg Terminal "just a website." The data curation and hallucination-free output are the product, not the inference layer.